IN CASE YOU MISSED IT: Yesterday, Slate published a must-read op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this thought-provoking and timely piece, Lane highlights the importance of ensuring transparency around the taxpayer costs for COVID-19 drug research so American patients are guaranteed a fair price when a coronavirus drug comes to […]

Continue Reading

WHAT YOU NEED TO KNOW This week, amid public outcry and pressure from groups like CAPA, drugmaker Gilead withdrew its request for the FDA to grant orphan-drug status for remdesivir, an experimental drug that is being tested as a possible treatment for COVID-19. Receiving orphan-status would have given Gilead a seven-year monopoly on a potential cure in […]

Continue Reading

“We Need More Competition And Not Less To Address This Pandemic” WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) released the following statement regarding today’s announcement by Gilead that it is withdrawing its request for extended monopoly rights on potential Covid-19 treatment remdesivir and will ask the FDA to revoke the drug’s special “orphan drug” […]

Continue Reading

WHAT YOU NEED TO KNOW Last week, the JAMA Network published a must-read study which found that from 2007 to 2018, the net price of brand-name prescription drugs rose by 60 percent. First reported on by Axios, this study emphasizes the growing obstacle everyday Americans face when trying to afford the often lifesaving prescription drugs they need.  To […]

Continue Reading

IN CASE YOU MISSED IT: As first reported by Axios, a new must-read study from the JAMA Network found that between 2007 and 2018, the net price of brand-name prescription drugs rose by 60 percent. These findings underscore the financial challenges faced by American patients trying to afford the often life-saving prescription drugs they need. A significant driver of […]

Continue Reading